US Stock Insider Trading | Ligand disclosed two insider transactions on March 5

On March 5, 2026, Ligand (LGND) disclosed two transactions involving company insiders.

On March 3, 2026, director Sabba Stephen L sold 2,034 shares.

【Recent Insider Transactions】

【Company Profile】

Ligand Pharmaceuticals Incorporated was incorporated in Delaware in 1987 and is a biopharmaceutical company. The company’s business model is to develop or acquire assets that can generate revenue, integrate them into the cost structure of lean enterprises, and create sustainable profitable businesses to generate value for shareholders. Because the company’s business model is based on collaborating with other pharmaceutical companies, commercially leveraging and selling the assets, a substantial portion of the company’s revenue comes from royalties related to their usage provided by partners. The company recognized the importance of drug re-formulation in the pharmaceutical industry, and in 2011 it added the CAPTISOL project to its technology investments. CAPTISOL is a powerful formulation technology with five drug products approved by the U.S. Food and Drug Administration, including Pfizer’s VFEND IV and Baxter International’s Nexterone, along with several other partner programs that are used in clinical-stage deployments. Compared with other peer companies, the company has built what is the industry’s largest diversified asset portfolio, which can generate significant revenue in the future. The therapeutic programs developed within the asset portfolio can address many unmet medical needs gaps, including hepatitis, muscle atrophy, senile dementia, dyslipidemia, diabetes, anemia, asthma, rheumatoid arthritis, and osteoporosis.